News

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...
Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study results published ...
"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...
The maximum ramucirumab infusion rate was 25 mg/min. Trastuzumab was administered as an IV infusion at a loading dose of 4 mg/kg for cycle 1, day 1, and a dose of 2 mg/kg for the subsequent ...
trastuzumab can be given intravenously or as an injection under the skin (subcutaneously) Phesgo is given as an injection under your skin; As an injection under your skin. The most common way to have ...
Tucatinib, trastuzumab and capecitabine is a combination of cancer drugs. It is a treatment for locally advanced or metastatic breast cancer. Find out more. ... You have trastuzumab as an injection ...
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, ... (IV) EG12014 at a dose of 150 mg. Under a licensing agreement signed in April 2019, ...
Trastuzumab is available as injection: In a single vial of injection, 600 mg trastuzumab and 10,000 units hyaluronidase is available. How should Trastuzumab with Hyaluronidase be taken?
Shenzhen, China--(Newsfile Corp. - June 26, 2023) - Recently, Kexing Biopharm (688136.SH) signed with Chia-Tai Tianqing (CTTQ) an exclusive cooperation agreement for overseas commercialization of ...
SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki induced encouraging response rates among certain patients with early breast cancer, according to findings presented at San Antonio Breast Cancer ...
If you have early-stage HER2-positive breast cancer, here’s good news: There are more treatment options than ever. They can help you live longer while you enjoy a good quality of life.